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PPARγ ligands have been shown to have antiproliferative eﬀects on many cell types. We herein report that a synthetic dominant-
negative (DN) PPARγ mutant functions like a growth factor to promote cell cycle progression and cell proliferation in human
coronary artery smooth muscle cells (CASMCs). In quiescent CASMCs, adenovirus-expressed DN-PPARγ promoted G1→Sc e l l
cycle progression, enhanced BrdU incorporation, and increased cell proliferation. DN-PPARγ expression also markedly enhanced
positive regulators of the cell cycle, increasing Rb and CDC2 phosphorylation and the expression of cyclin A, B1, D1, and MCM7.
Conversely, overexpression of wild-type (WT) or constitutively-active (CA) PPARγ inhibited cell cycle progression and the activity
and expression of positive regulators of the cell cycle. DN-PPARγ expression, however, did not up-regulate positive cell cycle
regulators in PPARγ-deﬁcient cells, strongly suggesting that DN-PPARγ eﬀects on cell cycle result from blocking the function
of endogenous wild-type PPARγ.D N - P P A R γ expression enhanced phosphorylation of ERK MAPKs. Furthermore, the ERK
speciﬁc-inhibitor PD98059 blocked DN-PPARγ-induced phosphorylation of Rb and expression of cyclin A and MCM7. Our data
thus suggest that DN-PPARγ promotes cell cycle progression and cell growth in CASMCs by modulating fundamental cell cycle
regulatory proteins and MAPK mitogenic signaling pathways in vascular smooth muscle cells (VSMCs).
Copyright © 2009 Joey Z. Liu et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
VSMC proliferation is an early response to the arterial
wall injury, as well as the primary event in more extensive
vascular remodeling associated with increased intima-media
thickness and atherosclerotic lesions [1]. Both damaged and
activated VSMCs secrete growth factors and cytokines that
trigger multiple mitogenic signaling pathways, including
the Ras/Raf/MEK/ERK signaling cascade [2]. ERK activa-
tion induces cyclin D1 expression and thus facilitates the
formation of the cyclinD1-CDK4/6 complex, the key step
for quiescent cells to undergo cell cycle entry [3]. Active
cyclinD1-CDK4/6 complexes phosphorylate retinoblastoma
protein (Rb), releasing sequestered E2F bound to hypophos-
phorylated Rb to promote transcription of key cell cycle
genes required for S phase DNA replication [4]. E2F release
induces the expression of regulatory proteins involved in the
initiation step of chromosomal DNA replication, such as the
minichromosome maintenance (MCM) proteins, which are
recruited to replication origins during the G1 phase of the
cell cycle, establishing the competence of these origins for
initiation of DNA replication in the subsequent S phase [5].
Several groups, including our own, have shown that
PPARγ ligands, such as the thiazolidinediones (TZDs),
inhibit VSMC proliferation and cell cycle progression in
vitro [6–11] and intimal hyperplasia in vivo [7]. Despite
extensive study, however, the mechanism(s) underlying the
antiproliferative eﬀect of PPARγ ligands in VSMC remain to
bedetermined.RareandnaturalPPARγ mutationshavebeen
associated with insulin resistance, hypertension, and vas-
cular hypertrophy [12–14], with the majority of mutations
reported to date found in the ligand-binding domain (LBD)
of the receptor [15]. Gurnell et al. [16] created an artiﬁcial
PPARγ LBD mutant by introducing L486A and E471A
amino acid substitutions. This mutant exhibited dominant-
negative activity, suppressing the activity of cotransfected
WT PPARγ and blocking TZD-induced adipogenesis in 3T3-
L1 preadipocytes. The profound dominant-negative eﬀects2 PPAR Research
of this mutant were attributed to impaired release of core-
pressors (NCoR and SMRT) and diminished recruitment of
coactivators (CBP and SRC). A DN-PPARγ construct has
been shown to promote neointima formation in balloon-
injured rat arteries and enhance VSMC proliferation and
migration [17]. They reported that injury-induced intima-
media ratio (IMR) was reduced in animals infected with
adenovirus expressing WT PPARγ;h o w e v e r ,r a t si n f e c t e d
with adenovirus expressing DN-PPARγ demonstrated sig-
niﬁcantly greater IMRs than untreated controls, regardless
of PPARγ ligand treatment. Recently, Meredith et al. [18]
demonstrated that VSMC isolated from transgenic mice
harboring a dominant-negative mutation of PPARγ showed
greater proliferation and migration compared to VSMC
isolated from wild-type mice.
Based on these studies, we hypothesized that a DN-
PPARγ mutant would antagonize WT-PPARγ activity to
abrogate or reverse its eﬀects on VSMC cell growth. We
therefore examined the eﬀect of DN-PPARγ expression on
cell cycle progression, G1 to G2/M cell cycle regulators, and
MAPK mitogenic signaling pathways in VSMCs and found
that DN-PPARγ promoted the expression and activity of
positive regulators of the cell cycle, G1→S progression and
cellproliferation,andthattheseeﬀectsweremediatedinpart
through ERK activation.
2.MaterialsandMethods
2.1. Cell Culture. Primary human CASMCs and SmGM-2
and SmBM cell culture media were purchased from Cambrex
(Walkersville, MD). Early passage (four to nine) CASMCs
were cultured to ∼75% conﬂuence in SmGM-2 growth
medium, then cultured from 24 to 48 hours in SmBM basal
medium supplemented with 0.4% FBS to induce cell cycle
arrest. Mouse PPARγ-deﬁcient embryonic stem (ES) cells
were kindly provided by Dr. R. Evans (Howard Hughes Med.
Ins., Lo Jolla, CA) and described previously [19]. Murine
primary embryonic ﬁbroblasts used as ES feeder cells were
purchased from Stem Cell Technologies (Vancouver, BC,
Canada). ES cells were maintained and diﬀerentiated with
ES-Cult products (Stem Cell Technologies) according to the
manufacturer’s protocols.
2.2. Adenovirus Procedures. An expression vector containing
full-length human wild-type PPARγ1[ 20] was kindly pro-
vided by Dr. Alex Elbrecht (Merck Research Laboratories,
Whitehouse Station, NJ), and used to create the DN-PPARγ
double-mutant described by Gurnell et al. [16] by mutations
of L468A and E471A using a QuikChange Multi Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA). An
expression vector containing a constitutively-active mouse
PPARγ1 (CA-PPARγ) mutant, created by fusing the herpes
simplex VP16 transactivation domain to the N-terminus of
mouse WT PPARγ1[ 21], was a kind gift from Dr. Barry For-
man (City of Hope National Medical Center, Duarte, CA).
An expression vector encoding the VP16 transactivation
domain only (pTet/VP16) was purchased from Clontech.
Adenovirus expressing WT-PPARγ (Ad-WT), DN-PPARγ
(Ad-DN), CA-PPARγ (Ad-CA), the VP16 transactivation
domain (Ad-VP16), and the green ﬂuorescent protein (Ad-
GFP) were created with the Adeno-X Expression System
(Clontech, Mountain View, CA) according to the manu-
facturer’s protocol, conﬁrmed by DNA sequencing, then
expanded in HEK293 cells and puriﬁed with Adeno-X Virus
Puriﬁcation Kits (Clontech). Viral titers were determined
with Clontech Adeno-X Rapid Titer Kit, and virus was
used at multiplicity-of-infection (MOI) rates of 20 to 80
infectious particles per cell, as indicated. CASMCs were
growth-arrested by culture in SmBM basal medium with
0.4% of FBS for 24 to 48 hours, as indicated, before 48
hours infection with adenovirus. Speciﬁed cultures were
supplemented with or without serum, growth factors, or the
ERK MAPK inhibitor PD98059 (Cell Signaling Technology,
Danvers, MA) at the indicated times and conditions.
2.3. Luciferase Assays. NIH/3T3 cells (American Type Cul-
ture Collection, Manassas, VA) were transfected for 48 hours
with 1μgD N - ,W T - ,o rC A - P P A R γ plasmid DNA, and 5ng
of CMV-renilla luciferase (pRL-CMV; Promega, Madison,
WI) and 1μg of acyl-CoA oxidase PPAR Response Element
(PPRE, 3x)-tk-ﬁreﬂy luciferase DNA (kind gift of Dr. Peter
Tontonoz, UCLA) using LipofectAMINE 2000 (Invitrogen,
Rockville, MD) according to the manufacturer’s protocol.
After 24 hours transfection, cells were treated with 10μM
rosiglitazone (RSG) in DMSO or DMSO alone. Luciferase
activity was assayed 48 hours after transfection with the
Dual Luciferase Reporter Assay System (Promega) follow-
ing the manufacturer’s instructions. PPRE-driven ﬁreﬂy
luciferase activity was normalized to CMV-driven renilla
luciferase activity to adjust for diﬀerences in transfection
eﬃciency.
2.4. Cell Cycle Analysis. After serum-starvation, CASMCs
used for cell cycle analysis were infected with virus for
48 hours with or without PDGF plus insulin, and then
resuspended by trypsinization, centrifuged for 5 minutes
at 250×g, washed with PBS, centrifuged for 5 minutes
at 250×g, and aspirated to remove supernatant from the
cell pellet. CASMC cell pellets were then resuspended in
DNA staining buﬀer (3.4mM sodium acetate, 0.3% Triton
X-100, 1.5mM propidium iodide, and 20μg/mL RNase A)
and incubated at 4◦C for 30 minutes. Nuclei staining data
was acquired by ﬂow cytometry using a Becton Dickinson
FACScan, and the proportion of cells in G0/G1, S, and G2/M
phase were determined using Becton Dickinson ModFit LT
software.
2.5. DNA Synthesis and Cell Proliferation Assays. CASMCs
used for BrdU incorporation and cell proliferation assays
were grown to ∼75% conﬂuence in 60-mm plates, serum-
starved for 48 hours in SmBm basal medium containing
0.4%FBS,andinfectedfor48hourswithadenovirusexpress-
i n gG F P ,D N - ,o rC A - P P A R γ. Cells were then resuspended
by trypsinization and replated in 96-well plates at a density
of 1 × 104 c e l l s / w e l la n dc u l t u r e df o r3d a y si nS m B m
basal medium containing 0.4% FBS. BrdU incorporationPPAR Research 3
analyseswerethencarriedoutusingacommerciallyavailable
BrdU immunoassay (Calbiochem, San Diego, CA) according
to the manufacturer’s instructions. Cells used for DNA
proliferation analysis were infected with virus for 48 hours
and then recultured in 12-well plates at 5 × 104 cells/well for
another3daysinSmBmbasalmediumcontaining0.4%FBS.
Cells were then resuspended by trypsinization and counted
with a hemocytometer.
2.6. Western Blot Analyses. CASMC whole cell lysates were
generated as previously described [22], size fractionated by
SDS-PAGE, and transferred onto Hybond ECL nitrocellulose
membrane (Amersham Biosciences, Piscataway, NJ) prior to
Western blot analysis. Speciﬁc antibodies for phospho-Rb
(Ser807/811), phospho-cdc2 (Thr161), cyclin D1, phospho-
and total ERK (p44/42), and horseradish peroxidase con-
jugated secondary antibodies were purchased from Cell
Signaling Technology. Cyclin A (sc-751), MCM7 (sc-9966),
p21 (sc-6246), p27 (sc-1641), and PPARγ (sc-7196) speciﬁc
antibodies were purchased from Santa Cruz Biotechnology.
Speciﬁc antibodies to cyclin B1 (05-158; Millipore), GFP
andβ-actin(Abcam,Cambridge,MA),andVP16(Clontech)
were purchased from the indicated companies. Speciﬁc
antibody hybridization was detected using ECL reagents
and X-ray ﬁlm (Amersham), and resulting signals were
quantiﬁed by densitometry. Western blot protein expression
was normalized against β-actin, except pERK1/2, which was
normalized against total ERK1/2.
2.7. Statistical Analyses. Data are presented as mean ± stan-
dard error of the mean (SE). Diﬀerences between individual
groups were analyzed by 2-tailed Student’s t-test or 1-way
analysis of variance (ANOVA) followed by Tukey-Kramer
posttests to determine diﬀerences between individual means
when comparing multiple groups. A P-value ≤ .05 was
considered statistically signiﬁcant for all tests.
3. Results
3.1. DN-PPARγ Expression Completely Inhibits WT-PPARγ
Activity. NIH/3T3 ﬁbroblasts, which do not express
detectable PPARγ [23], were transfected with a PPRE-
luciferase reporter vector and plasmids expressing WT-,
DN-, or CA-PPARγ, or empty expression vector in the
presence or absence of the PPARγ ligand RSG (Figure 1).
Ligand treatment increased luciferase activity 3-fold in cells
transfected with WT-PPARγ vector. Cells transfected with
CA-PPARγ vector revealed a greater than 13-fold increase
in luciferase activity compared to those transfected with
empty expression vector constructs. Transfection with DN-
PPARγ, with or without RSG, did not result in appreciable
change of luciferase activity compared to the basal level.
However, when cotransfected with WT-PPARγ, the mutant
PPARγ repressed WT-PPARγ transcriptional activity by 58%
(Figure 1). These data agree with previously reported results
[16], conﬁrming that the L486A/E471A double-mutant
PPARγ behaves as a dominant-negative that fully suppresses
wild-type PPARγ activity.
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Figure 1: PPRE-mediated transcriptional activity of WT-, DN-,
and CA-PPARγ. NIH/3T3 ﬁbroblasts were transiently transfected
with a PPRE(3x) ﬁreﬂy luciferase reporter vector and a pRL-CMV
renilla luciferase expression construct with or without plasmids
expressingWT-,DN-,orCA-PPARγ.After24hoursoftransfection,
cells were treated with or without 10μM rosiglitazone (RSG).
Luciferaseactivitywasassayed48hoursaftertransfection,adjusting
for transfection eﬃciency by normalizing ﬁreﬂy luciferase activities
to renilla luciferase activity. All transfections were performed a
minimum of three times. Data are expressed as the ratios of ﬁreﬂy
to renilla luciferase activity and presented as mean ± SE (∗P<. 05
versus all other conditions by 1-way ANOVA).
3.2. DN-PPARγ Promotes G1→S Progression and Cell
Growth. In order to assess the eﬀect of DN-PPARγ expres-
sion on cell-cycle progression, CASMCs were serum starved
to induce cell cycle arrest at G0/G1, infected with Ad-GFP,
Ad-CA, or Ad-DN, then treated with PDGF plus insulin
to stimulate cell cycle progression. Flow cytometry analysis
(Figure 2) showed that CASMCs infected with Ad-GFP had
cell cycle proﬁles similar to noninfected cells at all stages of
the cell cycle, both during growth arrest and stimulation.
CASMCs infected with Ad-DN, however, demonstrated
signiﬁcant decreases in the number of cells in the G0/G1
phase of the cell cycle when compared to uninfected and
Ad-GFP infected cells, both during growth arrest (65.0%
versus 77.2% and 76.9%) and stimulation (39.4% versus
57.0% and 55.8%). Serum-starved CASMCs infected with
Ad-DN demonstrated an increased percentage of S phase
cells, relative to uninfected and Ad-GFP infected CASMCs
(22.6% versus 11.3% and 12.5%), but revealed a similar
percentage of cells in G2/M. Stimulation of these cells with
PDGF and insulin increased the percentage of S phase and
G2/M phase cells, but Ad-DN infected cells had a greater
percentage of cells in both S and G2/M than any of the other
samples.
Serum-starved CASMCs infected with Ad-CA were not
signiﬁcantly diﬀerent from noninfected or Ad-GFP infected
cells at any stage of the cell cycle. However, Ad-CA-infected
CASMCs induced with PDGF and insulin demonstrated4 PPAR Research
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Figure 2: DN-PPARγ promotes CASMC cell cycle G1→S progression. CASMCs were cultured in serum-depleted medium (0.4% FBS) for
48 hours to induce cell cycle arrest, then infected with or without (−) adenovirus expressing GFP, DN-PPARγ,o rC A - P P A R γ (MOI of 40).
After 24 hours, cells were cultured with vehicle (white bars) or with 20ng/mL PDGF plus 0.1μM insulin (grey bars) for 24 hours to induce
cellproliferationandthenharvestedandstainedwithpropidiumiodide.ThefractionsofG0/G1,S,andG2/Mphasecellsineachsamplewere
determined by measuring the DNA content of 1 × 106 cells per sample by ﬂow cytometry. Results presented represent the mean ± SE of at
least four independent experiments. (∗P<. 05 versus no virus (−), Ad-GFP and Ad-CA; ∗∗P<. 05 versus no virus and Ad-CA; and †P<. 05
versus no virus, Ad-GFP and Ad-DN for the matching culture condition by 1-way ANOVA; ‡P<. 05 versus matching serum-stimulated
culture by Student’s t-test).
marked attenuation of cell cycle progression, demonstrating
cell cycle proﬁles that appeared no diﬀerent from those of
growth arrested CASMCs. As shown in Figure 3(a),D N A
synthesis measured by BrdU incorporation was signiﬁcantly
increased in Ad-DN-infected CASMCs (2.8-fold versus Ad-
GFP), conﬁrming the ability of DN-PPARγ to stimulate
G1→S progression under serum starvation conditions.
These ﬁndings demonstrate that in CASMCs DN-PPARγ
expression promotes G1→S transition, and that CA-PPARγ
expression can completely block mitogen-stimulated cell
cycleprogression.Thisdataagreedwellwithpreviousreports
that indicate that PPARγ l i g a n d sc a ns u p p r e s sc e l lc y c l e
progression, since dominant-negative suppression of PPARγ
activity promoted G1→S progression in both quiescent and
simulated CASMCs, while constitutively-active PPARγ did
n o ta p p e a rt oa ﬀect the G1→S phase transition in quiescent
cells but completely attenuated the G1→S phase increase
normally observed upon growth stimulation with PDGF and
insulin.
Since DN-PPARγ stimulated G1→S cell cycle progres-
sion and DNA synthesis, even in the absence of exogenous
mitogens, we next examined the ability of DN-PPARγ to
promote cell cycle progression through G2/M to promote
CASMC proliferation. As shown in Figure 3(b),a f t e r3 - d a y
culture under serum-starvation, Ad-DN-infected CASMCs
demonstrated a signiﬁcant increase in cell number when
compared to Ad-GFP-infected cells (2.1-fold versus 1.2-
fold starting cell number, resp.). Conversely, Ad-CA-infected
CASMCs revealed a signiﬁcant decrease in cell number (0.8-
fold starting cell number), which may be explained by our
previous data indicating that PPARγ ligands can induce
VSMC apoptosis [22].PPAR Research 5
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Figure 3: DN-PPARγ stimulates DNA synthesis and cell prolifera-
tion of quiescent CASMCs. Cells were cultured in serum-depleted
medium (0.4% FBS) for 48 hours to induce cell cycle arrest, then
infected with Ad-GFP, -DN or -CA (MOI = 40) for 48 hours. (a)
Cells were trypsinized, counted, and reseeded into 96-well plates
at a density of 1 × 104 cells/well. N = 3 wells/sample. After
3 days culture in serum-depleted medium, incorporation of the
BrdU thymidine analog was assayed using a commercially available
immunoassay(∗P<. 05versusAd-GFPcontrol).(b)Afterinfection
withvirus,cellswerereseededin12-wellplatesatadensityof5×104
cells/well and cultured in serum-depleted medium. After 3 days,
cells were harvested and counted on a hemocytometer to measure
cell proliferation. N = 4-5 counts/sample (∗P<. 05 versus Ad-GFP
control; †P<. 05 versus Ad-GFP control and Ad-DN).
3.3. DN-PPARγ Induces the Expression of Key Regulatory Cell
Cycle Proteins. Since the induction of cell cycle progression
and cell growth by DN-PPARγ expression likely resulted
from changes in cell cycle checkpoint proteins, we examined
the expression of key regulatory proteins required for
progression through the G0/G1, S, and G2/M cell cycle
checkpoints and the expression of two cyclin-dependent
kinase inhibitors (CDKIs) known to regulate the activity of
several checkpoint proteins.
As shown in Figure 4, CASMCs infected with Ad-
DN strikingly upregulated the activity of several genes
required at cell cycle checkpoints, increasing Rb phospho-
rylation (G1→S), cyclin A expression (S→G2 and G2→
M), MCM7 expression (S phase DNA synthesis), and cyclin
B1 expression/CDC2 phosphorylation (G2→M), and these
eﬀects were predominantly dose-dependent. For example,
in serum-starved CASMCs, Ad-DN, at MOI 40, increased
cyclin B1 (2-fold), p-CDC2 and MCM7 (4-fold), pRb (8-
fold)andcyclinA(19-fold)versusserum-starved,uninfected
cells. Serum induced similar increases in the expression of
these proteins (cyclin B1, p-CDC2 and MCM7 3- to 4-fold,
pRb 14-fold, and cyclin A 20-fold). Comparable results were
observedwhen20ng/mLPDGFplus0.1μMinsulinwasused
to stimulate cells proliferation instead of 5% FBS (data not
shown). Ad-GFP had no eﬀect on basal or serum-stimulated
expression of these proteins, while in the absence of
serum stimulation Ad-WT suppressed only MCM7 expres-
sion. Ad-DN dose-dependently increased serum-induced
cell cycle protein expression. Ad-DN infection at 40MOI
only increased cyclin A (2-fold), while Ad-DN at 80 MOI
increased p-CDC2, pRb, and cyclin A expression (2- to 3-
fold), under serum-stimulation condition. By contrast, Ad-
WT and Ad-CA suppressed serum-induced increases in pRb,
cyclin A, cyclin B1 and MCM7, but not p-CDC2. Ad-WT
decreased cyclin A and B1, MCM7 and pRb expression
to 30%–50% of serum-induced CASMC expression in the
absence of exogenous ligand. Ad-CA markedly reduced pRb
and cyclin A (2%-3% of serum control), cyclin B1 (12% of
control), and MCM7 (30% of control), demonstrating that
activated PPARγ strongly reduced the expression or activity
of these regulatory cell cycle proteins.
Surprisingly, Ad-DN infection also increased the protein
level of two important negative regulatory CDKIs, p21
and p27 (Figure 5), by approximately 2-fold versus either
uninfected or Ad-GFP infected samples. We did not observe
any Ad-DN eﬀect on CDKI p16 (data not shown). These
results suggest that DN-PPARγ expression regulates both
positive and negative regulators of cell cycle progression.
3.4. DN-PPARγ Eﬀect on Cell Cycle Is PPARγ Dependent. In
order to conﬁrm the role of PPARγ in the regulation of cell
cycle proteins, we examined the eﬀects of DN-PPARγ and
GFP expression on the expression of regulatory cell cycle
proteins in mouse PPARγ−/− embryonic stem (ES) cells [19].
Again, PPARγ−/− ES cells demonstrated marked induction
of cyclin A, MCM7, and pRb expression upon serum stimu-
lation (Figure 6). However, unlike our previous results with
Ad-DN-infectedCASMCs,Ad-DNinfectionofPPARγ−/− ES
did not induce cyclin A, MCM7, or pRb expression versus
Ad-GFP-infected cells under either serum-starvation or
-stimulation conditions. This did not appear to result from
diﬀerential PPARγ responses in ES versus CASMC, since Ad-
DN induction of cyclin A, MCM7, and pRb expression in
WT ES cells was similar to that observed in CASMCs (data
not shown). These data strongly suggest that DN-PPARγ
exerts its growth promoting eﬀects through attenuation of
an endogenous PPARγ activity to suppress cell proliferation.6 PPAR Research
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Figure 4: Ad-DN up-regulates, while Ad-WT and Ad-CA down-regulate, positive regulators of G0/G1, S, and G2/M phases. CASMCs
were arrested in serum-deprived medium for 24 hours, then infected with or without Ad-DN, -WT, -GFP, -VP16, or -CA recombinant
adenoviruses at the indicated MOIs for 48 hours, with or without serum stimulation. Western blot analyses were performed on whole cell
extracts of these samples using antibodies against the indicated cell cycle regulatory proteins, then stripped and rehybridized with a β-actin
speciﬁc antibody to assess loading variability. Western blots shown are representative of at least four independent experiments.
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Figure 5: Ad-DN expression up-regulates CASMC expression of
CDKIs p21 and p27. CASMCs were arrested in serum-deprived
medium for 24 hours, then infected with or without Ad-GFP
or -DN recombinant adenoviruses (MOI = 80) for 48 hours,
with or without serum stimulation. Western blot analyses were
performed on whole cell extracts of these samples using antibodies
speciﬁc for CDKIs p21 and p27, then stripped and rehybridized
with a β-actin speciﬁc antibody to assess loading variability.
Westernblotsshownarerepresentativeofatleastthreeindependent
experiments.
3.5.DN-PPARγ ActivatesERKs1/2toInduceExpressionofCell
Cycle Proteins. Serum or mitogenic growth factors induce
phosphorylation of the mitogen activated protein kinases
ERK 1 and ERK 2, activating signal transduction cascades
that promote cell growth. Activated ERK 1/2 regulate the cell
cycle, in part, by transducing signals to the nucleus that leads
to increased expression of cyclin D1, a key protein in the
regulation of the G1 to S phase transition [2, 24]. Serum and
Ad-DN similarly induced CASMC ERK1/2 phosphorylation
(2- and 3-fold, resp.) and cyclin D1 protein expression
(10- and 19-fold, resp.), both of which were attenuated by
the ERK speciﬁc-inhibitor PD98059 (Figure 7(a)). Similarly,
treatment of CASMCs with PD98059 also attenuated DN-
PPARγ-mediated induction of several positive cell cycle
β-actin
PPARγ
MCM7
Cyclin A
p-Rb
FBS (5%) + − + − + −
Ad-DN Ad-GFP Virus −
Figure 6: DN-PPARγ does not up-regulate phospho-Rb, cyclin
A, or MCM7 in PPARγ-deﬁcient embryonic stem cells. PPARγ−/−
ES cells were diﬀerentiated and then growth arrested in serum-
deprived medium for 24 hours, then infected with or without Ad-
GFP, -DN, or WT recombinant adenovirus (MOI = 80) for 48
hours, with or without serum stimulation. Western blot analyses
were performed on whole cell extracts of these samples using
antibodies speciﬁc for the indicated regulatory cell cycle proteins,
then stripped and rehybridized with a β-actin speciﬁc antibody to
assess loading variability. Western blots shown are representative of
at least three independent experiments.
regulators (Figure 7(b)), suggesting that the previously
observed cell cycle and growth eﬀects of DN-PPARγ were
mediated, at least in part, through activation of the ERK1/2
signaling pathway. Moreover, PD98059 treatment markedly
attenuated DN-PPARγ-mediated Rb phosphorylation and
cyclin A and MCM7 expression, but increased p27 expres-
sion, suggesting that DN-PPARγ stimulates the expression of
positive and negative regulators of the cell cycle via diﬀerent
mechanisms.PPAR Research 7
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Figure 7: DN-PPARγ-mediated induction of cell cycle regulators is ERK MAPK-dependent. (a) Ad-DN induced phosphorylation of
ERK1/2 and expression of cyclin D1, which are inhibited by the ERK MAPK inhibitor PD98059. (b) PD98059 inhibits DN-PPARγ-induced
upregulation of phospho-Rb, cyclin A, and MCM7 but increases p27 expression. CASMCs were arrested in serum-deprived medium for 48
hours, cultured with 30μM PD98059 for 30 minutes prior to infection with or without Ad-GFP or -DN recombinant virus for 48 hours, in
theabsenceofserum.Westernblotanalyseswereperformedonwholecellextractsofthesesamplesusingantibodiesspeciﬁcfortheindicated
proteins, then stripped and rehybridized with a β-actin speciﬁc antibody to assess loading variability. Western blots shown are representative
of at least three independent experiments.
4. Discussion
In the present study, we demonstrate that a dominant-
negative PPARγ mutant harboring L486A/E471A substitu-
tions in its LBD is a potent activator of cell cycle progression
and cell proliferation in quiescent (serum-starved) human
CASMCs.WefoundthatRbandCDC2phosphorylationand
expression of cyclins A and B1, and MCM7 were strongly
induced after quiescent CASMCs were infected with Ad-DN,
generally in a dose-dependent manner. Thus, the mitogenic
activity of DN-PPARγ is likely mediated through these cell
cycle regulatory proteins. Serum stimulation of Ad-DN-
infected CASMCs further upregulated these proteins, while
serum-induced increases in these proteins were substantially
inhibited by Ad-WT or Ad-CA. Our in vitro results are
consistent with recent reports that DN-PPARγ represses the
antiproliferative eﬀects of WT-PPARγ and increases intima
formation in rat and mouse arteries and promotes VSMC
proliferation and migration [17, 18]. Lim et al. [17] have also
reportedthatDN-PPARγ upregulatestheexpressionofc-fos,
an important component of the MAPK mitogenic signaling
pathway.
These data further help to explain important functions
of PPARγ in the vasculature, which have been deﬁned in
mouse models which harbor a vascular-speciﬁc knockout of
the nuclear receptor. Recently, Halabi et al. [14] developed
a transgenic mouse with VSMC-speciﬁc expression of a DN-
PPARγ LBDmutantsimilartotheL486A/E471APPARγ LBD
mutantthatwedescribeinthisreport.Thismousedeveloped
hypertension, impaired nitric oxide-mediated vasodilation,
an enhanced endothelin vasoconstriction response, and
vascular hypertrophy with altered arteriolar remodeling.
This mouse also demonstrated a robust increase in vas-
cular osteopontin, an adhesion molecule that we have
demonstrated plays a key role in accelerated atherosclerosis,
and whose expression can be suppressed by PPARγ ligand
treatment [25]. Mice with cre/ﬂox-generated endothelial- or
VSMC-speciﬁc PPARγ deﬁciency have also been shown to
develop hypertension, although no histology was presented
for these models and their vasodilator and vasoconstrictor
responses were opposite to those reported for the VSMC
DN-PPARγ mouse model [26]. Both of the cre/ﬂox mod-
els also demonstrated a blunting of diurnal variation in
blood pressure and heart rate [26]. Recently, Chang et al.
demonstrated that VSMC-speciﬁc PPARγ KO mice exhibit
impairedvasoactivityandhypotensionwhichcorrelatedwith
enhanced beta-2-adrenergic activity [27]. Taken together,
these studies suggest that PPARγ has important eﬀects
on vascular function, including regulation of cardiovas-
cular rhythms, blood pressure, and VSMC proliferation,
underscoring the importance of deﬁning the mechanisms
mediating these actions.
CDK inhibitors, such as p21 and in particular, p27,
are generally regarded as potent negative regulators in
the cascade of G1 events induced by growth factors. In
the present study, both p21 and p27 expressions were
upregulated by DN-PPARγ, although to a lesser degree than
positive cell cycle regulators. CDKIs can prevent quiescent
cells from entering cell cycle by inhibiting CDK activity
and preventing Rb phosphorylation [28]. In this study,
however, we found that DN-PPARγ expression induced
robust phosphorylation of Rb even in the presence of high
levels of p27 and p21 and that the end result favored cell
cycle progression. Data emerging from recent studies suggest
that CDKIs p21 and p27 can also play a positive role in
events during the G1 phase. Both CDKIs are required for
cyclin D assembly with CDK4 and its stability and nuclear
localization [29], and p27 levels were signiﬁcantly associated
with cyclin D1 and E expression in some breast cancer cell
lines [30, 31]. We have also reported that PPARγ ligands
inhibit Rb phosphorylation and G1→S transition in rat
aortic VSMC [6]. In that study, we found that PDGF plus8 PPAR Research
insulin induced VSMC p21 expression and enhanced p27
degradation, while PPARγ activation attenuated mitogen-
induced p21 expression, perhaps contributing to the G1
arrest of VSMC in response to PPARγ ligands. Hence, the
prevailing view of CDKIs as universal inhibitors of CDKs
may portray too simple a picture of their regulatory eﬀects
on the cell cycle [29].
The Ras/Raf/MEK/ERK signaling cascade appears to be
indispensable for cell proliferation in a variety of diﬀerent
cell types [3]. ERK regulates the production of materials
required for cell growth, including pyrimidine and ribosome
synthesis [3], and transient expression of ERK1 antisense
RNA or a kinase-deﬁcient ERK1 mutant has been shown
to decrease cell growth [32]. ERK activation also plays a
key role in G1→S phase transition. Formation of cyclin
D-CDK4/6 complexes is a key step for quiescent cells to
enter the cell cycle, and activation of the ERK pathway is
known to increase cyclin D1 expression, while inhibition of
ERK activity by expression of a dominant negative form of
MEK has been shown to decrease cyclin D expression [33].
We previously reported that the PPARγ ligand troglitazone
inhibited mitogen-induced MAPK signaling downstream of
ERK phosphorylation and activation in VSMC, which was
associated with a suppression of growth and ERK MAPK-
controlled expression of MCM6 and MCM7, which are
central components of a DNA replication complex [7, 34].
WealsofoundthatbothPPARγ ligandsandtheERKspeciﬁc-
inhibitor PD98059 inhibited mitogen-induced p27 degrada-
tionandcyclinD1up-regulation,contributingtothedelayed
G1→S transition of these cells [6]. In the present study,
we found that DN-PPARγ expression potently activated Rb
and ERK phosphorylation and cyclin D1 expression, all
of which were attenuated by pretreatment with PD98059.
Taken together, these data strongly suggest that DN-PPARγ
regulates CASMC proliferation, at least in part, by inducing
ERK 1/2 phosphorylation to activate cyclin D1 expression,
and that the resulting cyclin D1-CDK4/6 complexes in turn
phosphorylate Rb to promote G1→S progression.
Further studies are necessary to deﬁne the exact mech-
anism by which DN-PPARγ increases ERK MAPK activity.
PPARγ may be active under basal conditions, in the absence
ofpharmacologicligands, dueto the presenceof endogenous
ligands such as oxidized fatty acids, which we have recently
shown to reside in the large binding pocket of PPARγ and
to activate it in a biologically relevant manner (unpublished
data). We found that medium chain C8-C10 fatty acids
produced by the bacteria from which the crystallized nuclear
receptor was cloned, and which are abundant in many
foods, could stabilize Helix 12 of PPARγ into an active
conformation, as demonstrated by its ability to promote
adipocyte diﬀerentiation, a well-known function of PPARγ.
DN-PPARγ expression might therefore block basal CASMC
PPARγ activity, induced by endogenous ligands, which
might otherwise suppress the ERK MAPK pathway. Gurnell
et al. [13] previously demonstrated an impressive ability of
this double mutant DN-PPARγ construct to silence basal
transcriptional activity, which was associated with increased
corepressor association. We found basal PPARγ activity to
be about 30% of the activity obtained upon addition of
pharmacologicligand(Figure 1),similartothe25%reported
by Gurnell et al. [13]. Thus, it appears likely that these cells
contain endogenous PPARγ ligands, which may suppress cell
growth in a PPARγ-speciﬁc manner. This suggestion is sup-
portedbyourobservationthatoverexpressionofWT-PPARγ
in the absence of synthetic ligand speciﬁcally suppresses
positive cell cycle regulatory protein expression (Figure 4),
while DN-PPARγ expression does not alter cell cycle regu-
lators in the absence of PPARγ (Figure 6). Stimulation by
FBS and DN-PPARγ diﬀered only in their eﬀect on p27
and p21, which were decreased by the former and increased
by the latter, but the cause and impact of these diﬀer-
ences remains unclear. Surprisingly, DN-PPARγ-stimulated
ERK1/2 phosphorylation in serum-starved CASMC was
equivalent to that induced by 5% FBS and lead to similar
changes in cell cycle regulators, suggesting that endogenous
PPARγ ligands may have a substantial growth suppressive
eﬀect. Interestingly, Meredith et al. also observed a modest
inductionofmitogen-independentERKactivationinserum-
starved VSMCs derived from mice expressing DN-PPARγ
(P465L), compared to VSMCs from mice expressing only
wild-type PPARγ [18] .T h em o r er o b u s te ﬀect on mitogen-
independent ERK activation we observe after adenoviral
overexpression of DN-PPARγ may be due to the much
higher levels of expression achievable through our in vitro
approach. Meredith et al. found that DN-PPARγ-expressing
VSMCs exhibited enhanced proliferation and migration and
they suggested that this eﬀect could be mediated, at least in
part, through Ets-1, which we have previously shown to be
regulated by ERK signaling in VSMCs [35].
Excessive growth of VSMCs contributes to the for-
mation of atherosclerotic and restenotic lesions. However,
the growth-promoting capacity of DN-PPARγ could prove
beneﬁcial in several gene therapy settings where reactivation
of a dormant cell cycle would be desirable. For instance,
proliferation of adult pancreatic islet cells is limited [36],
and increasing their growth capacity could be beneﬁcial for
treatment of type I and II diabetes. The heart has little,
if any, potential for regeneration after injury, since adult
cardiac myocytes are terminally diﬀerentiated cells that do
not proliferate. Many studies have attempted to induce
cardiocmyocyte proliferation by overexpressing cell cycle
regulatory molecules to promote cell cycle progression [37].
The potential for DN-PPARγ, or compounds that mimic
its eﬀects, to promote reactivation of the cell cycle in these
settings merits further exploration.
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